FICARE 2024

08:10 - 08:22
Is Magnetic resonance useful to select patients for local treatment in early rectal cancer?

GINA BROWN

Speaker

08:22 - 08:34
When transanal Local excision for pT1 ALONE is enough? Preliminary data from the TESAR trial & intermuscular dissection

ROEL HOMPES

Speaker

08:34 - 08:46
Chemotherapy and Local Excision for early rectal cancers? The NEO trial.

CARL BROWN

Speaker

08:46 - 08:58
GRECCAR 12 – The use of neoadjuvant Folfirinox for organ-preservation

QUENTIN DENOST

Speaker

08:58 - 09:10
Local excision after nCRT or TNT? When and how?

JULIO GARCIA AGUILAR

Speaker

09:10 - 09:30
Discussion

09:30 - 09:38
Intermuscular Local excision for early rectal cancer

ROEL HOMPES

Speaker

09:38 - 09:46
Completion TME after initial local excision – is it a nightmare?

QUENTIN DENOST

Speaker

09:46 - 10:00
Discussion

10:30 - 10:42
Total Neoadjuvant Therapy for the achievement of a cCR?

GUILHERME PAGIN SÃO JULIÃO

SAO PAULO / SP Speaker

10:42 - 10:54
Short-course or Long-course when WW is the goal? The German trial and current data available.

EMMANOUIL FOKAS

Speaker

10:54 - 11:06
Long-course RT + Contact radiation leads nearly 90% organ preservation – Why anything else?

SUN MYINT

Speaker

11:06 - 11:18
Isn’t TME (without RT or chemotherapy) a better option?

ROEL HOMPES

Speaker

11:18 - 12:00
Discussion

12:00 - 12:15
The anatomical landmarks and challenges for each compartment in pelvic exenteration.

GINA BROWN

Speaker

12:15 - 12:30
Level of sacral resection – what are the limits?

QUENTIN DENOST

Speaker

12:30 - 12:45
The recurrent lateral pelvic node long after TME

TSUYOSHI KONISHI

Speaker

12:45 - 13:00
Discussion

14:00 - 14:12
PRODIGE – Why FOLFIRINOX should be the new normal in all locally advanced rectal cancer

THIERRY CONROY

Speaker

14:12 - 14:24
PROSPECT – Can we avoid radiation? When and for whom can we eliminate RT?

DEBORA SCHRAG

Speaker

14:24 - 14:36
OPRA - Is organ-preservation main-stream now? What still needs to be done? Lessons learned from the OPRA trial

JULIO GARCIA AGUILAR

Speaker

14:36 - 14:48
Current status of MSI rectal cancer managed by immunotherapy – Where are we at?

ANDREA CERCEK

Speaker

14:48 - 15:00
Elderly and Frail patients with locally advanced disease – How to balance treatment morbidity

EMMANOUIL FOKAS

Speaker

15:00 - 15:30
Discussion

17:00 - 17:12
Radiological Assessment - How nodal staging became less relevant than other radiological features for the decision management in rectal cancer?

GINA BROWN

Speaker

17:12 - 17:24
MR quality in rectal cancer – How heterogenous is the quality of MR and how it impacts decision management?

CINTHIA ORTEGA

SAO PAULO / SP Speaker

17:24 - 17:36
How tridimensional vascular reconstruction may help surgeon plan/perform rectal cancer surgery

PATRICIA TEJEDOR

Speaker

17:36 - 17:48
What about lateral pelvic nodes? Pre or post treatment findings to consider lateral node dissection?

TSUYOSHI KONISHI

Speaker

17:48 - 18:15
Discussion

08:00 - 08:10
Retroperitonial approach for the left colon – When you do not want to get into the abdomen…

SERGEY EFETOV

Speaker

08:10 - 08:20
Lateral node dissection – the role of ICG

GYU-SEOG CHOI

Speaker

08:20 - 08:30
What is a proper D3 dissection in upper rectal cancer

SERGEY EFETOV

Speaker

08:30 - 08:40
Robotic TME – How I do it – step by step

LAURA FERNANDEZ

Speaker

08:40 - 08:50
Combined TME & prostatectomy with the use of robot

GYU-SEOG CHOI

Speaker

08:50 - 09:10
Discussion

09:10 - 09:20
The “perfect” lateral node dissection with the robot – Tips and tricks

GYU-SEOG CHOI

Speaker

09:20 - 09:30
Lateral node in the setting of a complete clinical response

GUILHERME PAGIN SÃO JULIÃO

SAO PAULO / SP Speaker

09:30 - 09:40
Lateral node dissection without preoperative treatment – Is there a role? What to do with a patient with a 7mm node in the absence of other high-risk factors?

TSUYOSHI KONISHI

Speaker

09:40 - 10:00
Discussion

10:30 - 10:40
When double-stapling is the preferred strategy and new stapling alternatives

BRUNA VAILATI

SAO PAULO / SP Speaker

10:40 - 10:50
Transrectal transection and single-stapled anastomosis x Pull-through – Choosing one or the other?

QUENTIN DENOST

Speaker

10:50 - 11:00
Diversion or no diversion – Who should not be diverted and why?

ROEL HOMPES

Speaker

11:00 - 11:10
Why ICG SHOULD be implemented into routine clinical practice

QUENTIN DENOST

Speaker

11:10 - 11:20
Partial mesorectal excision – It’s all about the level of transection…

ROEL HOMPES

Speaker

11:20 - 12:00
Discussion

13:30 - 13:42
What happens when mrEMVI+ become ymrEMVI-?

GINA BROWN

Speaker

13:42 - 13:54
What is a near-complete clinical response and how to deal with it?

JULIO GARCIA AGUILAR

Speaker

13:54 - 14:06
Local regrowths & the risk of distant metastasis – are we really at risk?

LAURA FERNANDEZ

Speaker

14:06 - 14:30
Discussion

16:00 - 16:10
Robotic TME with synchronous liver metastasis resection

PATRICIA TEJEDOR

Speaker

16:10 - 16:20
Management of anastomotic leaks – aggressive transanal approach

ROEL HOMPES

Speaker

16:20 - 16:30
Minimally invasive para-aortic nodal dissection

TSUYOSHI KONISHI

Speaker

16:30 - 16:40
Intraoperative bleeding during lateral pelvic node dissection

TSUYOSHI KONISHI

Speaker

16:40 - 16:50
Minimally invasive Deloyers Procedure

LEONARDO ERVOLINO CORBI

SÃO PAULO / SP Speaker

16:50 - 17:10
Discussion

17:10 - 17:22
Is there a place for Immunotherapy in MSS rectal cancer?

ANDREA CERCEK

Speaker

17:22 - 17:34
Can we increase organ-preservation by intensifying treatment? JANUS trial

JOSH SMITH

Speaker

17:34 - 17:46
ctDNA in rectal cancer – what is the role in adjuvant chemotherapy decision management? Can we extrapolate data from colon cancer?

ANDREA CERCEK

Speaker

17:46 - 18:10
Discussion